PLA2G4A and breast carcinoma: Inhibiting lipid metabolism in effector T cells through reprogramming with group IVA phospholipase A2 (PLA2G4A) has a favorable effect on preventing ex vivo T cell senescence, which has been validated in mouse models of melanoma and breast cancer [99].